Literature DB >> 2083541

Radiochemical purity of D,L-hexamethylpropylene amine oxime and analysis of urine-excreted HMPAO decomposition species.

V Ivancević1, Z Kuster, Z Mastrović, D Ivancević.   

Abstract

The radiochemical purity of hexamethylproxypropylene amine oxime (HMPAO) was determined in 16 preparations using the three-strip method. Immediately post-formulation, 90.3% +/- 4.0% (mean +/- SD) of the activity was associated with the primary lipophilic complex having an Rf of 0.45 +/- 0.11. We recorded a significantly higher content of sodium pertechnetate Tc 99m in methylethyl ketone (MEK) (21.1% +/- 8.5%) than in saline (5.0% +/- 3.7%; P less than 0.001). To clarify this finding, we ran sequential chromatograms (t = 0, 1, 2, 3 h) and found that the primary complex steadily disappeared, with a rate constant of 0.31 h-1. These results suggest that there is a decomposition of the primary complex during chromatography in MEK that might be responsible for the larger fraction of sodium pertechnetate Tc 99m in MEK. Eluate composition might influence the Rf of the lipophilic complex and the rate of its in vitro decomposition. In another experimental setting, we investigated 99mTc-HMPAO decomposition species in urine after application of a suspension of labelled leukocytes by performing sequential chromatographic analyses in 11 patients. At 1 h after application, urinary activity reflected the presence of a secondary complex (84.8% +/- 9.2%) and sodium pertechnetate Tc 99m (15.2% +/- 9.2%). The values after 3 h were markedly different (91.4% +/- 4.8% and 8.6% +/- 4.8%; P less than 0.001). Thus, urinary activity mostly consisted of a secondary complex, increasing with time.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2083541     DOI: 10.1007/BF00819401

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  11 in total

1.  Cerebral perfusion imaging.

Authors:  J R Ballinger; K Y Gulenchyn
Journal:  J Nucl Med       Date:  1987-08       Impact factor: 10.057

2.  The in vivo distribution of 99Tcm-HM-PAO in normal man.

Authors:  D C Costa; P J Ell; I D Cullum; P H Jarritt
Journal:  Nucl Med Commun       Date:  1986-09       Impact factor: 1.690

3.  Technetium-99m HM-PAO stereoisomers: differences in interaction with glutathione.

Authors:  J R Ballinger; R H Reid; K Y Gulenchyn
Journal:  J Nucl Med       Date:  1988-12       Impact factor: 10.057

4.  Inflammation: imaging with Tc-99m HMPAO-labeled leukocytes.

Authors:  M E Roddie; A M Peters; H J Danpure; S Osman; B L Henderson; J P Lavender; M J Carroll; R D Neirinckx; J D Kelly
Journal:  Radiology       Date:  1988-03       Impact factor: 11.105

5.  Kinetic analysis of technetium-99m d,1-HM-PAO decomposition in aqueous media.

Authors:  J C Hung; M Corlija; W A Volkert; R A Holmes
Journal:  J Nucl Med       Date:  1988-09       Impact factor: 10.057

6.  The behavior of 99mTc-hexamethylpropyleneamineoxime (99mTc-HMPAO) in blood and brain.

Authors:  K Nakamura; Y Tukatani; A Kubo; S Hashimoto; Y Terayama; T Amano; F Goto
Journal:  Eur J Nucl Med       Date:  1989

7.  A 99Tcm-labelled radiotracer for the investigation of cerebral vascular disease.

Authors:  P J Ell; J M Hocknell; P H Jarritt; I Cullum; D Lui; D Campos-Costa; D P Nowotnik; R D Pickett; L R Canning; R D Neirinckx
Journal:  Nucl Med Commun       Date:  1985-08       Impact factor: 1.690

8.  Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imaging.

Authors:  D P Nowotnik; L R Canning; S A Cumming; R C Harrison; B Higley; G Nechvatal; R D Pickett; I M Piper; V J Bayne; A M Forster
Journal:  Nucl Med Commun       Date:  1985-09       Impact factor: 1.690

9.  Technetium-99m d,l-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion.

Authors:  R D Neirinckx; L R Canning; I M Piper; D P Nowotnik; R D Pickett; R A Holmes; W A Volkert; A M Forster; P S Weisner; J A Marriott
Journal:  J Nucl Med       Date:  1987-02       Impact factor: 10.057

10.  Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies.

Authors:  P F Sharp; F W Smith; H G Gemmell; D Lyall; N T Evans; D Gvozdanovic; J Davidson; D A Tyrrell; R D Pickett; R D Neirinckx
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.